Pegylated Rhg-Csf

Breast Cancer

Jiangsu HengRui Medicine Co., Ltd.Phase 3Dormant

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 56/ 100
Competitive Position: 59/ 100

Competitive context

891 Active assets in the Breast Cancer cohort.

Asset / Sponsor	Phase	Rating
Lapatinib University of New Mexico	Phase 3	BBB
Darolutamide Vandana Abramson	Phase 2	BBB
Trastuzumab Duocarmazine Byondis B.V.	Phase 3	BB
ERIBULIN MONOMETHANESULFONATE Henan Cancer Hospital	Phase 4	BB
Palbociclib Hoffmann-La Roche	Phase 4	BB

View all 50 →

Same molecule, other indications

Pegylated Rhg-Csf is also rated in:

Febrile NeutropeniaDormant

BB

Indicative ·

69 / 100

non-Hodgkin lymphomaDormant

BB

Indicative ·

65 / 100

neutropeniaDormant

BB

Indicative ·

64 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.